[18F]AlF-NOTA-FAPI-04 PET/CT在转移灶中的摄取可能区分不同病理类型的肺癌
前瞻性纳入61例经组织病理学证实的原发性肺癌伴转移患者,治疗前注射235.10 ± 3.89 MBq [18F]AlF-NOTA-FAPI-04后1小时行PET/CT,比较原发灶与转移灶SUVmax。原发灶各病理类型间摄取无差异(P=0.198),但不同病理类型转移灶间摄取有差异(P<0.001),骨转移摄取最高。FAPI摄取与FAP表达呈正相关。
要点
- 原发灶ADC、SCC与SCLC间[18F]AlF-NOTA-FAPI-04摄取无差异(P=0.198)。
- 转移性淋巴结SUVmax以SCC最高,其次ADC,SCLC最低(P<0.001)。
- 骨转移摄取在SCC和ADC中高于淋巴结及其他器官(P<0.05),SCLC中无此差异。
核心结论
- [18F]AlF-NOTA-FAPI-04 PET/CT显示肺癌转移灶FAP表达存在差异,骨转移中表达最高,可能有助于区分不同病理类型的肺癌。
研究设计与样本
- 前瞻性纳入61例经组织病理学证实的原发性肺癌伴转移患者,治疗前注射235.10 ± 3.89 MBq [18F]AlF-NOTA-FAPI-04后1小时行PET/CT。
- 纳入腺癌(ADC)30例、鳞状细胞癌(SCC)17例、小细胞肺癌(SCLC)14例;评估61个原发肿瘤和199个转移灶。
- 对肿瘤标本行FAP免疫组织化学染色,分析FAPI摄取与FAP表达的相关性。
主要发现
- 原发ADC、SCC与SCLC肿瘤间[18F]AlF-NOTA-FAPI-04摄取无差异(P=0.198)。
- 同一病理类型的肺癌原发灶与转移灶间摄取无差异(P>0.05)。
- 不同病理类型转移灶间摄取有差异(P<0.001);转移性淋巴结SUVmax以SCC最高,其次ADC,SCLC最低(P<0.001)。
- 骨转移SUVmax亦以SCC最高,其次ADC和SCLC(P<0.05),但ADC与SCLC间无差异;其他器官转移中SCC高于ADC,SCC与SCLC间、ADC与SCLC间无差异。
- SCC和ADC中骨转移摄取高于淋巴结和其他器官转移(P<0.05),SCLC中无此差异;手术加活检标本中FAPI摄取与FAP表达正相关(r=0.439,P=0.012),手术标本中r=0.938,P=0.005。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Heterogeneity is found in the tumor microenvironment among different pathological types of tumors. Radionuclide-labeled fibroblast-activation-protein inhibitor (FAPI), as an important tracer for non-invasive imaging of the tumor microenvironment, can be used to evaluate the expression of FAP in cancer-associated fibroblasts, macrophages, and tumor cells. Our aim was to explore the ability of [18F]AlF-NOTA-FAPI-04 positron emission tomography (PET)/computed tomography (CT) to distinguish different types of lung cancer by evaluating the uptake of this tracer in primary and metastatic lesions. METHODS: We prospectively enrolled 61 patients with histopathologically proven primary lung cancer with metastases. PET/CT scanning was performed before any antitumor therapy and 1 h after injection of 235.10 ± 3.89 MBq of [18F]AlF-NOTA-FAPI-04. Maximum standard uptake values (SUVmax) were calculated for comparison among primary and metastatic lesions. Immunohistochemical staining for FAP was performed on tumor specimens. RESULTS: Sixty-one patients with adenocarcinoma (ADC, n = 30), squamous cell carcinoma (SCC, n = 17), and small cell lung cancer (SCLC, n = 14) were enrolled in this study, and 61 primary tumors and 199 metastases were evaluated. No difference in [18F]AlF-NOTA-FAPI-04 uptake was observed among primary ADC, SCC, and SCLC tumors (P = 0.198). Additionally, no difference in uptake was found between primary and metastatic lesions of lung cancer with the same pathological type (P > 0.05). However, uptake did differ among metastases of differing pathological types (P < 0.001). The SUVmax of metastatic lymph nodes was highest for SCC, followed by ADC and then SCLC (P < 0.001). The SUVmax of bone metastases also was highest for SCC, followed by ADC and SCLC (P < 0.05), but no difference was observed between ADC and SCLC. The SUVmax of metastases in other organs was higher in SCC cases than in ADC cases but did not differ between SCC and SCLC or ADC and SCLC. Bone metastases exhibited higher uptake than those of lymph nodes and other organs in SCC and ADC (P < 0.05) but not in SCLC. Positive correlations were found between FAPI uptake and FAP expression in surgical plus biopsy specimens (r = 0.439, P = 0.012) and surgical specimens (r = 0.938, P = 0.005). CONCLUSION: [18F]AlF-NOTA-FAPI-04 PET/CT imaging revealed differences in FAP expression in metastases of lung cancer, with the highest expression specifically in bone metastases, and thus, may be valuable for distinguishing different pathological types of lung cancer.
引用
- Wei Y, Cheng K, Fu Z, et al. [18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34870727. doi:10.1007/s00259-021-05638-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。